On Friday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), Tidewater Inc. (NYSE:TDW), Metalico Inc. (NYSEMKT:MEA), Quiksilver Inc. (NYSE:ZQK)
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), with shares drowned -68.61%, closed at $2.74, hitting new 52-week low of $2.72.
Tidewater Inc. (NYSE:TDW), with shares dropped -2.93%, settled at $19.58, hitting new 52-week low of $19.37.
Metalico Inc. (NYSEMKT:MEA), with shares dipped -21.35%, and closed at $0.460.
Quiksilver Inc. (NYSE:ZQK), plummeted -15.56%, and closed at $1.90.
Latest NEWS regarding these Stocks are depicted underneath:
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)
On Friday, Ohr Pharmaceutical, Inc. (OHRP), declined after the news that the company declared the topline results from the exploratory Phase II INFLUENCE study evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD). In the intent-to-treat (ITT-LOCF) population with classic containing choroidal neovascularization (CNV) (OHR-102 n=38, Lucentis(R) monotherapy n=32), 42% of the patients receiving OHR-102 achieved a >=3 line gain at nine months, as contrast to 28% in the Lucentis monotherapy group. Less of a benefit was seen in the overall population (classic containing and occult only CNV lesions). The classic containing CNV population represents about two thirds of the total wet-AMD population. The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to raise through the end of the study, supporting the planned Phase III development program.
In patients with classic CNV (ITT-LOCF), mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. The mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different. Detailed data will be presented at the forthcoming Association for Research in Vision and Ophthalmology (ARVO) scientific meeting, which will take place May 3rd — 7th.
“We believe the final data from the INFLUENCE study demonstrates a positive and clinically meaningful treatment effect of OHR-102 combination therapy in classic containing CNV. This benefit is consistent with the mechanism of OHR-102 and historical combination therapy studies,” stated Dr. Jason Slakter, Chief Medical Officer of Ohr and retina specialist at Vitreous-Retina-Macula Consultants of NY. “Now that the full data from the Phase II study is accessible, we are thoroughly evaluating all of the underlying factors that may have contributed to variability in patient response. These analyses will assist guide and optimize the design of the Phase III trials of OHR-102 in wet-AMD.”
OHR Pharmaceutical, Inc., a pharmaceutical corporation, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease.
Tidewater Inc. (NYSE:TDW)
Joseph M. Bennett, Executive Vice President and Chief Investor Relations Officer of Tidewater Inc. (TDW), presented at the Scotia Howard Weil 43rd Annual Energy Conference in New Orleans, Louisiana on Monday, March 23, 2015.
Tidewater Inc. provides offshore service vessels and marine support services through the operation of a fleet of marine service vessels to the offshore energy industry worldwide.
Metalico Inc. (NYSEMKT:MEA)
Metalico Inc. (MEA), has declared plans to delay filing its Annual Report on Form 10-K for the year ended December 31, 2014 for up to fifteen days from the current target date of March 31.
The Corporation has filed a Notification of Late Filing with the U.S. Securities and Exchange Commission for the Annual Report, allowing the Corporation to file its 2014 10-K by April 15. Metalico intends to release its results for 2014 and the fourth quarter and host an earnings call by that date.
Metalico stated that it is in talks with its senior secured lenders about future compliance with terms of its debt as a result of further downturns in the scrap industry and their influence on the Corporation’s financial statements. These factors may affect the presentation of certain items in the 2014 Annual Report and, accordingly, the Corporation will not be able to file the report by March 31, 2015.
Metalico continues to meet all its obligations to its various constituencies and is focused on maintaining a sustainable capital structure pending improvement in its business.
Metalico, Inc., through its auxiliaries, is engaged in scrap metal recycling and lead metal product fabricating businesses. It collects and processes ferrous and non-ferrous metals; collects industrial and obsolete scrap metals, and processes them into reusable forms; and supplies the recycled metals to consumers, counting electric arc furnace mills, integrated steel mills, foundries, secondary smelters, aluminum recyclers, and metal brokers.
Quiksilver Inc. (NYSE:ZQK)
Quiksilver Inc. (ZQK), declared that Pierre Agnes, President of Quiksilver, Inc., has been promoted to Chief Executive Officer and added to the Board of Directors; he succeeds Andy Mooney who is no longer with the corporation. In addition, Greg Healy, Quiksilver’s APAC Region President, has been promoted to President of Quiksilver, Inc., and Bob McKnight has been designated Chairman.
Pierre Agnes has worked for Quiksilver for 27 years. In November 2014, he was promoted to President of Quiksilver, Inc. He formerly served as Global Head of Apparel for Quiksilver, Roxy and DC. Since 2005 Pierre served as President of Quiksilver Europe.
The corporation also declared that Thomas Chambolle, Quiksilver’s EMEA Region Chief Financial Officer, will be promoted to Chief Financial Officer of Quiksilver, Inc. effective April 3, 2015. He succeeds Richard Shields, who has resigned to pursue other opportunities. Shields has agreed to serve as a consultant to the corporation and resource to Chambolle.
Quiksilver, Inc. designs, develops, and distributes branded apparel, footwear, accessories, and related products primarily for men, women, and children. The corporation provides its products for various activities, counting casual and outdoor lifestyle associated with surfing, skateboarding, snowboarding, BMX and motocross, rally car, and other activities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
